免疫學(xué)技術(shù)在科研中的應(yīng)用-展示頁
2024-08-20 02:35本頁面
【正文】 GERY 39 (6): 941946 JUN 2022 Times Cited: 3 26. Shen L, Schroers R, Hammer J, et al. Identification of a MHC classII restricted epitope in carcinoembryonic antigen CANCER IMMUNOLOGY IMMUNOTHERAPY 53 (5): 391403 MAY 2022 Times Cited: 4 M, Kobayashi H, Lasarte JJ, et al. Identification and characterization of a Thelper peptide from carcinoembryonic antigen CLINICAL CANCER RESEARCH 10 (8): 28602867 APR 15 2022 Times Cited: 2 EH, van der Minne CE, Kruse M, et al. Identification of multiple HLADRrestricted epitopes of the tumorassociated antigen CAMEL by CD4(+) Th1/Th2 lymphocytes JOURNAL OF IMMUNOLOGY 172 (8): 50955102 APR 15 2022 Times Cited: 3 29. Johansen P, Stamou P, Tascon RE, et al. CD4 T cells guarantee optimal petitive fitness of CD8 memory T cells EUROPEAN JOURNAL OF IMMUNOLOGY 34 (1): 9197 JAN 2022 Times Cited: 7 30. Frazer IH Prevention of cervical cancer through papillomavirus vaccination NATURE REVIEWS IMMUNOLOGY 4 (1): 4654 JAN 2022 Times Cited: 37 31. Liu XS, Xu Y, Hardy L, et al. IL10 mediates suppression of the CD8 T cell IFNgamma response to a novel viral epitope in a primed host JOURNAL OF IMMUNOLOGY 171 (9): 47654772 NOV 1 2022 Times Cited: 6 32. Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer CLINICAL CANCER RESEARCH 9 (12): 42964303 OCT 1 2022 Times Cited: 27 33. Tuyaerts S, Michiels A, Corthals J, et al. Induction of Influenza Matrix Protein 1 and MelanAspecific T lymphocytes in vitro using mRNAelectroporated dendritic cells CANCER GENE THERAPY 10 (9): 696706 SEP 2022 Times Cited: 10 OJ Cancer vaccines: Between the idea and the reality NATURE REVIEWS IMMUNOLOGY 3 (8): 630641 AUG 2022 Times Cited: 108 。 Th細(xì)胞在 mCTL介導(dǎo)的腫瘤保護(hù)中作用的研究 相關(guān)說明 ? OT1 mice : 表達(dá) SIINFEKL特異性 TCR ? OVA： 雞卵白蛋白 ? OVA CTL epitope: SIINFEKL ? OVA Th epitope:ISQAVHAAHAEINEAGROVA （ OVT） ? RAG1 KO mice: ? C57BL/6 mice: ? IFA/CFA/KLH ? EG7 cell line ? EL4 cell line 相關(guān)步驟 ? mCTL and eCTL generation ? OT1細(xì)胞轉(zhuǎn)輸 RAG1基因敲除小鼠 ， 2天后以 OT1 TCR 特異性表位多肽 SIINFEKL 免疫 ； ? specific Th generation ? OVA 特異性和非特異性 Th表位 多肽免疫 C57BL/6小鼠以產(chǎn)生特異性和非特異性 Th細(xì)胞； ? mCTL transfer ? 記憶性 CTL轉(zhuǎn)輸已產(chǎn)生特異性和非特異性 Th的 C57BL/6 小鼠 ； ? tumor challenge ? 接種表達(dá) OVA抗原的腫瘤細(xì)胞 EG7； Generation of Ovalbuminspecific Memory CD8 T Cells. OT1 lymph nodes cells were transferred to RAG/ mice through tail vein injection, and mice were immunized with 50ug of SIINFEKL peptide in CFA 1 day later. At day 7 , 14 , 21, mice were sacrificed, and splenocytes or lymph nodes cells were isolated and analyzed. The percentage of CD44high, SIINFEKLspecific CD8 T cells was assessed by threecolor FACS staining with SIINFEKL MHC class I tetramer and antibodies to CD8 and CD44. Plots shown are gated on the SIINFEKL tetramer positive lymphocytes。 ? 可以用于藥物篩選的動(dòng)物模型。 ? 通過同源重組產(chǎn)生目標(biāo)基因缺失或失活的轉(zhuǎn)基因動(dòng)物可以確定被敲除的基因在體內(nèi)代謝過程中的作用，還可確定被敲除基因在分化、發(fā)育、生存等過程中的作用和必要性。 ? MHC分子可為工類或 Ⅱ 類分子，與抗原肽形成的四聚體復(fù)合物，可分別鑒定表達(dá)特異性 TCR的 CD8+T細(xì)胞及CD4+T細(xì)胞的頻率。 ? 抗原特異性四聚體能與樣品中的特異性 T細(xì)胞的 TCR結(jié)合，由于四聚體能同時(shí)結(jié)合一個(gè) T細(xì)胞表面的 4個(gè) TCR，親和力大大提高。 ? 棄細(xì)胞懸液，重新解離細(xì)胞與磁珠。 ? 將特異性抗體 (如抗 CD抗 CD抗 CD8等 )吸附在鐵顆粒 (磁珠 )上，加
醫(yī)療健康相關(guān)推薦
鄂ICP備17016276號(hào)-1